US OptionsDetailed Quotes
FBIO241115C7500
- 0.05
- 0.000.00%
15min DelayClose Nov 6 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume4 Open Interest7.50Strike Price0.00Turnover541.67%IV328.98%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0972Delta0.1159Gamma35.20Leverage Ratio-0.0137Theta0.0000Rho3.42Eff Leverage0.0005Vega
Fortress Biotech Stock Discussion
Sign in to post a comment
$Fortress Biotech (FBIO.US)$ On FDA PDUFA Calendar for BLA of DFD-29 for treatment of lesions and erythema of rosacea in adults on 11/04/2024![]()
2
4
$Fortress Biotech (FBIO.US)$ should pump a little off MBIO if it gets running regular hours by Tutes
$Fortress Biotech (FBIO.US)$ TBIO made me look.. ;) almost time.. grab a starter if your patient instead of chasing 3-4 later on
$Fortress Biotech (FBIO.US)$ Fortress Biotech's Urica Therapeutics Entered Into An APA Royalty Agreement, Urica Sold The Rights To Its URAT1 Inhibitor Product Candidate In Development For The Treatment Of Gout, Dotinurad, And Related Intellectual Property, Licenses And Agreements To Crystalys Therapeutics In Return For Common Stock Equal To 35% Of Crystalys' Outstanding Equity
- SEC Filing
- SEC Filing
1
$Fortress Biotech (FBIO.US)$ Reuters· just
Fortress Biotech Inc: FDA Accepted Nda Filing for Dfd-29 to Treat Inflammatory Lesions & Erythema of Rosacea in Adults; Pdufa Goal Date of Nov 4, 2024
Fortress Biotech Inc: FDA Accepted Nda Filing for Dfd-29 to Treat Inflammatory Lesions & Erythema of Rosacea in Adults; Pdufa Goal Date of Nov 4, 2024
2
6
$Fortress Biotech (FBIO.US)$ even after good resilt thus share is going down. holding since last 3 months now.
The low P/S ratio is likely due to investors' concerns about the company's poor revenue performance and underwhelming growth outlook. The company will need a significant change in fortune to justify a higher P/S ratio in the future.
$Fortress Biotech (FBIO.US)$ $Mustang Bio (MBIO.US)$ City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
4 MINUTES AGO, 5:00 AM EST
VIA BUSINESSWIRE
• Half of the enrolled patients had stable disease for at least two months, two showed partial response and two experienced complete response
• Nature Medicine paper highlights delivery of CAR T cell therapy directly to the brain, a technique Ci...
4 MINUTES AGO, 5:00 AM EST
VIA BUSINESSWIRE
• Half of the enrolled patients had stable disease for at least two months, two showed partial response and two experienced complete response
• Nature Medicine paper highlights delivery of CAR T cell therapy directly to the brain, a technique Ci...
2
5
$Fortress Biotech (FBIO.US)$ Fortress Biotech And Cyprium Therapeutics Announce $4.1M Grant From NINDS To Further ThenDevelopment Of AAV-ATP7A Gene Therapy For Menkes Disease
1
No comment yet
Xyno : Don’t overlook $Journey Medical (DERM.US)$ for the same
Trytosaveabit OP Xyno : Yes that’s the same days as well! GL
《Only》鑫鑫 : Two companies are cooperating.
SkinnyChick Trytosaveabit OP : Approximately 6 month left before cash runs out. Looks good